Dr. Lal Path Labs Limited has executed a Fifth Supplementary Trust Deed to amend its Employee Welfare Trust, incorporating the newly approved Restricted Stock Unit Plan 2025. The amendment was completed on December 9, 2025, and registered with the Sub-Registrar of Assurances in New Delhi on December 10, 2025.

New RSU Plan Integration

The trust deed amendment follows the shareholders' approval of the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025) through a special resolution passed on December 7, 2025. The modification ensures compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Trust Structure and Trustees

The Employee Welfare Trust operates under three designated trustees who will oversee the implementation of the new RSU plan:

• Mr. Munender Soperna: Group Chief Information & Digital Officer, aged 51 years
• Dr. Reena Nakra: Principal Director, Lab Management Technical Excellence, aged 53 years
• Mr. Manoj Kumar Garg: Group Chief Human Resources Officer, aged 57 years

Expanded Employee Benefit Plans

The amended trust deed now encompasses a comprehensive range of employee benefit schemes under the expanded definition of "Plan":

• Dr. Lal PathLabs Employee Stock Option Plan 2010 (ESOP 2010)
• Dr. Lal PathLabs Employee Share Purchase Scheme 2015 (ESPS 2015)
• Dr. Lal PathLabs Employee Restricted Stock Unit 2016 (RSU 2016)
• Dr. Lal PathLabs Employee Stock Option Plan 2022 (ESOP 2022)
• Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025)
• Any future employee benefit plans with provisions for modifications

Trust Evolution Timeline

The Employee Welfare Trust has undergone multiple amendments since its establishment:

Regulatory Compliance

The Fifth Supplementary Trust Deed maintains continuity with all previous amendments while specifically addressing the requirements of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The document establishes that in case of conflicts between different versions, the provisions of the Fifth Supplementary Trust Deed will prevail for matters specifically addressed therein.

The trust deed amendment represents Dr. Lal PathLabs' continued commitment to employee welfare through structured equity participation programs, ensuring regulatory compliance while expanding benefit options for eligible employees.

Dr. Lal PathLabs , a leading diagnostic chain in India, has announced that its shareholders have approved several significant corporate actions through a postal ballot. The voting saw the passage of seven resolutions with the requisite majority.

Approved Resolutions

1. Employee Restricted Stock Unit Plan: Shareholders approved the introduction of the 'Dr. Lal PathLabs Employee Restricted Stock Unit Plan' (RSU). This plan will offer up to 5,27,403 options, sourced from 3,19,023 fresh shares and 2,08,380 shares through secondary acquisition.

2. Increase in Authorized Share Capital: The company received approval to increase its authorized share capital from Rs. 107.96 crore to Rs. 200.00 crore.

3. Issuance of Bonus Equity Shares: Shareholders gave their nod to the 1:1 bonus share issue, where shareholders will receive one new fully paid-up equity share for every existing share held.

Bonus Share Issue and Dividend

The bonus issue will be funded by capitalizing up to Rs. 83.78 crore from the company's Securities Premium Account. This move comes as the company celebrates ten years of listing on stock exchanges.

Additionally, the Board has declared an interim dividend of 70% (Rs. 7.00 per share) for the current fiscal year.

Employee Stock Plans

With the approval of the new RSU plan, Dr. Lal PathLabs aims to enhance its ability to retain talent. The plan will be administered through the existing Dr. Lal PathLabs Employee Welfare Trust.

Simultaneously, the company is reducing the options reserve under its existing Employee Stock Option Plan from 12,50,278 to 7,22,875 options.

Financial Performance

For the second quarter of the current fiscal year, Dr. Lal PathLabs reported:

The company maintained a healthy growth trajectory with strong profitability. Sample volume grew by 10.30% to 25.40 million, while patient volume increased by 5.00% to 8.20 million.

Strategic Initiatives

Dr. Lal PathLabs continues to focus on deepening its technical expertise in high-complexity testing areas. The company has become the first lab in India to integrate a deep learning-based AI module for detecting lymph node metastasis in cancer cases.

The company's flagship "Swasthfit" program, an affordable bundled preventive health checkup package, contributed 26% to Q2 revenues.

Dr. Lal PathLabs is pursuing network expansion with a disciplined, cluster-based approach, reinforcing its leadership in core markets of North and East India while deepening reach into Tier-3 and Tier-4 towns.

The approval of these resolutions by shareholders paves the way for Dr. Lal PathLabs to implement its employee incentive schemes, expand its capital structure, and continue its growth trajectory in India's evolving diagnostic sector.